final analysis of distant metastasis-free survival in the keynote-716 study
Published 1 year ago • 204 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
2:31
pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
3:46
results from the keynote-716: pembrolizumab versus placebo after complete resection of high-risk...
-
1:05
3-year update from the keynote-942 trial: mrna-4157 (v940) pembrolizumab in resected melanoma
-
2:19
#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
-
6:52
expert report on novel data in (neo)adjuvant treatment of melanoma from asco 2022
-
25:50
melanoma | 2022 oneoncology conference
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
5:01
melanoma highlights from esmo 2021
-
6:25
combination targeted adjuvant therapy doubles relapse-free survival in stage iii melanoma
-
4:05
vaccine-immunotherapy combo for high risk melanoma: new data on distant metastasis-free survival
-
0:46
interpath-001: v940, a neoantigen therapy, with pembrolizumab in melanoma